Janvier G, Winnock S, Dugrais G, Vallet A, Dardel E, Serisé J M, Calen S, Vergnes C, Toulemonde F
Haemostasis. 1987;17(1-2):49-58. doi: 10.1159/000215558.
Thirty patients presenting with phlebographically confirmed deep venous thrombosis were treated with a very low molecular weight heparin fragment (CY 222) in an open and prospective phase-2 trial. A uniform dosage of 750 IC anti-factor Xa units/kg/day was administered subcutaneously for 10 days or more to patients whose thromboses were categorized as postsurgical (17 cases) or medical (13 cases). The clinical symptoms of venous thrombosis diminished in 93% of the patients overall. The extent of vascular clearing was assessed by an original scoring system which compared the pre- and posttreatment phlebographies. The effect of treatment was globally rated 'very good' (more than 75% lysis) in 37% of the patients, 'good' (about 50% lysis) in 40% and 'poor' (0-25% lysis) in 17%; the phlebographic thrombosis worsened in 6.6%. Little change occurred in laboratory tests exploring thrombolysis, but a strong anti-factor Xa activity was detected.
在一项开放的前瞻性2期试验中，对30例经静脉造影证实患有深静脉血栓形成的患者，使用一种极低分子量肝素片段（CY 222）进行治疗。对于血栓形成分类为术后（17例）或内科（13例）的患者，皮下注射750抗Xa因子国际单位/千克/天的统一剂量，持续10天或更长时间。总体而言，93%的患者静脉血栓形成的临床症状有所减轻。通过一种原始评分系统评估血管清除程度，该系统比较治疗前后的静脉造影。37%的患者治疗效果总体评为“非常好”（溶解超过75%），40%评为“好”（约50%溶解），17%评为“差”（0 - 25%溶解）；静脉造影显示血栓形成恶化的占6.6%。探索溶栓的实验室检查变化不大，但检测到较强的抗Xa因子活性。
